Bronchial Diseases Clinical Trial
— BRONCHOPROEMOfficial title:
Patient Reported Outcome and Experience Measures for Bronchoscopic Procedures
Verified date | March 2024 |
Source | Vitaz |
Contact | Jonas Yserbyt, MD,PhD |
Phone | +3237602327 |
jonas.yserbyt[@]vitaz.be | |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
'Patient-reported outcomes' (PROMS) and 'patient-reported experiences' (PREMS) are increasingly important parameters in evaluating and adjusting clinical procedures and strategies in healthcare. Validated disease-specific PROMS related to bronchoscopic procedures are not available and examples in the medical literature are very scarce.
Status | Recruiting |
Enrollment | 300 |
Est. completion date | December 30, 2025 |
Est. primary completion date | December 30, 2025 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age above 18 years - Patient referred for diagnostic flexible bronchoscopy - Procedure performed in outpatient setting Exclusion Criteria: - Patient unable to adequately respond to the contents of the patient questionnaire. - Procedure performed in hospitalised setting - Patient with active pregnancy |
Country | Name | City | State |
---|---|---|---|
Belgium | VITAZ | Sint-Niklaas |
Lead Sponsor | Collaborator |
---|---|
Vitaz |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Procedure-related dyspnea scale (VAS) | Procedure-related dyspnea scale (VAS) | 24 hours | |
Primary | Procedure-related pain scale (VAS) | Procedure-related pain scale (VAS) | 24 hours | |
Primary | Procedure related cough scale (VAS) | Procedure related cough scale (VAS) | 24 hours | |
Primary | General patient satisfaction | General patient satisfaction VAS scale | 24 hours | |
Secondary | Procedure-related complications: | bleeding + grading; pneumothorax; hypoxaemia; hypercapnia; respiratory rate; heart rate. | 24 hours | |
Secondary | Sedation-related complications | paradoxical agitation; GCS; hypoxaemia; hypercapnia | 24 hours | |
Secondary | Diagnostic yield | number of biopsies; histological diagnosis; DNA extraction. | 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03688074 -
Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)
|
Phase 2 | |
Recruiting |
NCT04319705 -
Anti-viral Effects of Azithromycin in Patients With Asthma and COPD
|
Phase 4 | |
Completed |
NCT02162576 -
Asthma Data Innovation Demonstration Project
|
N/A | |
Active, not recruiting |
NCT04222972 -
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
|
Phase 3 | |
Completed |
NCT00932802 -
Greatest International Antiinfective Trial With Avelox
|
N/A | |
Recruiting |
NCT06272370 -
Individualizing Treatment for Asthma in Primary Care
|
Phase 4 | |
Completed |
NCT00989521 -
Effect of PUR003 on Asthma
|
Phase 1 | |
Enrolling by invitation |
NCT04697446 -
External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC
|
||
Completed |
NCT01264055 -
Cross-sectional Characterization of Idiopathic Bronchiectasis
|
||
Withdrawn |
NCT00830427 -
A Study To Examine The Safety And Efficacy Of PF-00610355 In Moderately Asthmatic Subjects
|
Phase 2 |